Skip to main content
. 2005 Aug 23;93(5):504–509. doi: 10.1038/sj.bjc.6602750

Table 2. Evaluation of anticancer drugs by EMEA from 1995 to 2004: summary of the 48 studies used as basis for approval.

Clinical trial design (48 trials) Type of end point (primary) (48 trials) Difference in survival, when available (13 trials)
RCT 25 Survival 4 Range 0–3.7 months
SAT 19 Resp. rate 30 Mean 1.5 (months)
NC-RCT 4 TTP/PFS 14 Median 1.2 (months)

RCT=randomised clinical trial; SAT=single-arm trial; NC-RCT=noncomparative RCT; TTP=time to progression; PFS=progression-free survival.